Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | CTSG | P08311 | 1/20 | 0.59 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.59 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28248159 | 1.00 | NAAA (0.73) | NAAAPOLBLMNAL3MBTL1GAA | |
| SCHEMBL11338329 | 0.98 | NAAA (0.71) | NAAAPOLBLMNAL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL7763902 | 0.98 | NAAA (0.71) | NAAAPOLBLMNAL3MBTL1GAA | |
| SCHEMBL11348229 | 0.98 | NAAA (0.71) | NAAAPOLBLMNAL3MBTL1GAA | |
| SCHEMBL11341368 | 0.98 | NAAA (0.71) | NAAAPOLBLMNAL3MBTL1GAA | |
| Dimethylamine SCHEMBL15710136 | 0.96 | NAAA (0.69) | NAAAPOLBLMNAL3MBTL1GAA | |
| Naphthalene SCHEMBL28863780 | 0.94 | NAAA (0.67) | NAAAPOLBLMNAL3MBTL1GAA | |
| Formic Acid SCHEMBL5398978 | 0.93 | NAAA (0.65) | NAAAPOLBLMNAL3MBTL1GAA | |
| SCHEMBL17226037 | 0.93 | NAAA (0.65) | NAAAPOLBLMNAL3MBTL1GAA | |
| Fumaric Acid SCHEMBL5586485 | 0.91 | NAAA (0.63) | NAAAPOLBLMNAL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 639 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008754-A1 | N-SUBSTITUTED DERIVATIVES OF L-(L-PHENYL-3-ARYL)-LFF-PYRAZOL-4-YL)METHANAININE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATIONS | UNIV MEDYCZNY W LUBLINIE (PL) | 2026-01-08 | — | — | US | claimed |
| EP-4652156-A1 | N-SUBSTITUTED DERIVATIVES OF L-(L-PHENYL-3-ARYL)-LFF-PYRAZOL-4-YL)METHANAININE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATIONS | Uniwersytet Medyczny w Lublinie (PL) | 2025-11-26 | — | — | EP | claimed |
| WO-2024117922-A1 | N-SUBSTITUTED DERIVATIVES OF L-(L-PHENYL-3-ARYL)-LFF-PYRAZOL-4-YL)METHANAININE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATIONS | UNIWERSYTET MEDYCZNY W LUBLINIE (PL) | 2024-06-06 | — | — | WO | claimed |
| CN-109942537-B | ALDH2 agonist, preparation method and application thereof | 中国人民解放军第二军医大学 | 2023-11-17 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-110511215-A | A kind of aryl piperazines/piperidines and application thereof | UNIV FUDAN | 2019-11-29 | — | — | CN | claimed |
| CN-110167556-A | Thio-hydantoin androgen receptor antagonist for treating cancer | 詹森药业有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-104837832-B | GDF-8 inhibitors | 里格尔药品股份有限公司 | 2019-04-26 | — | — | CN | claimed |
| CN-105368611-B | Cleaning compositions | 东友精细化工有限公司 | 2018-12-07 | — | — | CN | claimed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| EP-0934264-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (US) | 1999-08-11 | — | — | EP | claimed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | claimed |
| CN-1190393-A | Diaryldiamine derivatives and their use as delta opioid (ANT)-agonists | SMITHKLINE BEECHAM SPA (IT) | 1998-08-12 | — | — | CN | claimed |
| WO-1998012177-A1 | PYRROLIDINYL AND PYRROLINYL ETHYLAMINE COMPOUNDS AS KAPPA AGONISTS | PFIZER INC. (JP) | 1998-03-26 | — | — | WO | claimed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | claimed |
| EP-0339976-A1 | Anti-tumour agents | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-02 | — | — | EP | claimed |
| EP-0052442-B1 | HETEROCYCLIC COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-11 | — | — | EP | claimed |
| US-4503054-A | VASODILATORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-05 | — | — | US | claimed |
| EP-0052442-A1 | Heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-05-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008754-A1 | N-SUBSTITUTED DERIVATIVES OF L-(L-PHENYL-3-ARYL)-LFF-PYRAZOL-4-YL)METHANAININE, METHOD FOR THEIR PRODUCTION AND THEIR APPLICATIONS | HTR1F, ADH5, HRH4 | NAAA 766/4885POLB 729/4885LMNA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.